shutterstock_1635580639_sundry_photography

Sundry Photography / Shutterstock.com

28 August 2020Big PharmaRory O'Neill

Genentech to face revived Hemlibra claims

Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

More on this story

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

More on this story

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York